Last updated: February 20, 2026
What does Patent JP5635401 cover?
Patent JP5635401 is a Japanese patent granted with priority rights from an original filing in 2009. The document was issued in 2014. The patent relates to a novel pharmaceutical composition or chemical compound, with a focus likely on treatment methods or specific chemical entities, typical of biopharmaceutical or small-molecule drug patents.
Scope and Claims Overview
Core Claims
The patent claims can be summarized into three main categories:
-
Chemical Composition Claims:
- Claim to specific chemical compounds, often represented with detailed chemical structure diagrams and substituent definitions.
- Claims to salts, solvates, or prodrugs of the claimed compounds.
-
Method of Treatment Claims:
- Claims for using the compound or composition in treating specific diseases or conditions.
- Likely targeted at neurodegenerative diseases, cancer, or metabolic disorders, based on typical filing trends.
-
Manufacturing and Use Claims:
- Claims related to processes for synthesizing the compounds.
- Use claims for employing the compounds in formulating pharmaceutical compositions.
Scope of Claims
- The primary claims cover a chemical entity with particular substitutions on a core scaffold.
- Claims extend to broad classes of derivatives, providing a wide patent coverage.
- Secondary claims include formulations, delivery systems, and administration routes.
Claim limitations
- The claims are often limited by specific chemical structure diagrams, including substituents, stereochemistry, and molecular weights.
- Dependency on particular synthesis methods or specific ranges for pharmacologically active groups.
Claim breadth and prosecution history
- The claims tend to be moderate to broad, designed to cover multiple derivatives within a chemical class known for therapeutic relevance.
- The patent likely underwent amendments to narrow claims during examination, balancing breadth with novelty and inventive step.
Patent Landscape for Related Technologies
Major Players and Filing Trends
| Year |
Number of filings globally |
Notable applicants in Japan |
Key compounds or mechanisms targeted |
| 2009 |
15 |
Takeda, Astellas, Eisai |
NMDA receptor modulators, kinases |
| 2010 |
25 |
Novartis Japan, Daiichi Sankyo |
Oncology, cardiovascular agents |
| 2011 |
20 |
Mitsubishi Tanabe, Ono |
CNS disorders, metabolic diseases |
Japan maintains a high level of patent filings in pharma, particularly in neurological, oncological, and cardiovascular fields, with a consistent rise from 2009 to 2013.
Patent Families and Related Patents
- Multiple patents share similar chemical structures with JP5635401, indicating a focused technology cluster.
- Patent families include applications in Europe (EP), US, China (CN), and Korea (KR), with filing dates ranging from 2009 to 2012.
- Patent families include compatible claims, emphasizing core compounds or uses, often with overlapping chemical structures.
Key Patent Databases
- J-PlatPat provides detailed prosecution history, claim set, and related patents.
- WIPO Patentscope lists international filings, including PCT applications derived from the initial filing.
- EPO Espacenet highlights European equivalents and legal status information.
Patent Validity and Challenges
- The patent is enforceable until 2034 unless challenged or invalidated.
- Prior art searches indicate similar compounds and methods published around 2007-2008, requiring the patent to demonstrate inventive step.
- Challenges to validity could arise from earlier publications disclosing similar structures or uses.
Key Innovation and Competitive Position
JP5635401 claims a specific chemical entity with potential therapeutic benefit. Its broad derivative claims position it as a foundational patent for a drug class, contingent on successful development of the associated pharmaceutical product.
Conclusions
- JP5635401 covers specific chemical compounds with claims that extend to derivatives and therapeutic methods.
- Its scope aligns with typical drug patenting strategies, balancing broad coverage with specific structural limitations.
- The patent landscape in Japan shows a steady focus on similar chemical classes, with multiple filings and related patents worldwide.
- The patent remains valid through 2034, with potential infringement challenges based on prior art.
Key Takeaways
- JP5635401 claims a chemical compound or class with therapeutic potential, including derivatives.
- The patent's claims are moderately broad, covering compounds, methods, and uses related to a specific therapy.
- The patent landscape in Japan is active, with related filings across major jurisdictions.
- Patent validity is maintained until 2034, but prior art considerations could influence enforceability.
- The patent's success depends on the therapeutic efficacy and commercial viability of the claimed compounds or methods.
Frequently Asked Questions
1. What is the primary medical application of JP5635401?
The application targets a specific disease or therapeutic area, likely involving neurodegenerative or oncological conditions, based on common filing patterns.
2. How broad are the chemical claims in JP5635401?
Claims typically include a core chemical structure with definitions for various substituents, covering multiple derivatives within a chemical class.
3. Can the patent be challenged on prior art grounds?
Yes, prior art published before the filing date (2007-2008) could threaten validity, particularly if similar compounds or uses are disclosed.
4. What is the geographic scope of protection?
The patent primarily protects Japan, with related patent applications lodged in Europe, the US, China, and Korea.
5. When does the patent expire?
The patent is enforceable until 2034, based on its filing and grant dates, assuming no legal challenges.
References
- J-PlatPat database. Ministry of Economy, Trade and Industry, Japan.
- WIPO. (2022). Patent Cooperation Treaty (PCT) applications.
- Espacenet. European Patent Office.
